CSPC Pharmaceutical (HKG:1093) obtained drug registration approval for its Cobamamide capsules from China's National Medical Products Administration, a Thursday Hong Kong bourse filing said.
The move came after the product was deemed to pass the consistency evaluation of quality and efficacy of generic drugs.
The product is a type of vitamin B12 drug indicated for the treatment of megaloblastic anemia, nutritional anemia, anemia during pregnancy, polyneuritis, radiculitis, trigeminal neuralgia, sciatica, and nerve palsy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.